Skip to main content

Table 1 Demographic characteristics of AS and OA patients and healthy controls

From: Increased CCL19 and CCL21 levels promote fibroblast ossification in ankylosing spondylitis hip ligament tissue

  Ankylosing spondylitis (AS) (n = 44) Osteoarthritis (OA) (n = 29) Healthy controls (HC) (n = 16)
Male/female 35/7 20/9 9/7
Age (y) 35.93 ± 11.30 43.48 ± 11.21 33.38 ± 5.88
HLA-B27 (+) 36 NA NA
ESR (mm/h) 42.29 ± 25.74 8.92 ± 8.26 NA
CRP (mg/L) 25.41 ± 19.75 9.56 ± 21.96 NA
BASDAI score 52.3 ± 14.7 NA NA
BASFI score 62.24 ± 17.98 NA NA
VAS score 5.26 ± 1.94 NA NA
BAS-G score 5.51 ± 1.56 NA NA
Disease duration (months) 155 ± 103 NA NA
Morning stiffness (min) 13 ± 16 NA NA
Serum CCL19 (pg/ml) 354.12 ± 75.49 304.55 ± 82.82 215.15 ± 50.20
Serum CCL21 (pg/ml) 535.33 ± 124.22 470.13 ± 79.75 390.92 ± 38.12
  1. The data are expressed as the means ± Standard deviation (SD). ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; VAS: Visual analog scale; BAS-G: Bath Ankylosing Spondylitis Patient Global Score. NA: Not applicable.